Tagomics, a biomarker discovery and diagnostics company, has announced it has been awarded £860k Innovate UK funding as part of the Biomedical Catalyst programme for the testing and development of innovative healthcare solutions from Innovate UK.
The Novo Nordisk Foundation has announced the latest edition of its annual Challenge Programme, where for the first time it is inviting researchers from outside Denmark, in the European Schengen area, Ireland and the UK.
Concept Life Sciences has announced key strategic appointments and advancements to further strengthen its services for the global pharmaceutical and biotechnology sectors.
BDD has opened its 122m² GMP manufacturing facility at BioCity near Glasgow, following an inspection by the Medicines and Healthcare products Regulatory Authority (MHRA) in March 2025.
Aelius Biotech, whose laboratory gut model is used to trial new drugs without the need for animal testing has raised £750,000 from the North East Venture Fund, supported by the European Regional Development Fund and managed by Mercia Ventures.
In its largest-ever funding initiative for early-career researchers, the Academy of Medical Sciences is investing £7.6 million to tackle urgent health challenges from Alzheimer’s disease, cancer and obesity to addiction and climate change impacts.
Zymewire has released its highly anticipated 2024 Biopharma Recap Report, offering data-driven insights into global biopharma funding, clinical trial activity, and biotech company formation over the prior year, based on data from biopharma companies.
As a specialist in scalable, secure corporate payment solutions, B4B Payments continues to enhance its support for the pharmaceutical sector, offering innovative, compliance-friendly solutions to streamline operations and improve financial processes.
Likarda announced a new grant from the Gates Foundation that supports the company’s proprietary Core-Shell Spherification (CSS) system to extend the therapeutic potential of a cost-effective cell-based therapy for infectious diseases.
TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, today announced the closing of its $31 million (£25 million) seed funding round.
